In the absence of diabetes specialists, primary care physicians who may not be well-versed in the cardiovascular benefits of GLP-1 RAs could be hesitant to modify therapies when glycaemic control is stable, and feel reluctant to prescribe these medications even for patients with cardiovascular disease [23, 25]. The gene discussed is GLP1R; the disease is cardiovascular disorder.